Cardarine (GW-501516) vs Tirzepatide
A side-by-side research comparison of Cardarine (GW-501516) and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardarine (GW-501516) | Tirzepatide |
|---|---|---|
| Full name | GW-501516 (Cardarine, Endurobol) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Discontinued in development (safety concerns; banned in sport) | FDA Approved |
| Mechanism | Activates the PPAR-delta nuclear receptor, shifting cells toward burning fat for fuel and upregulating genes involved in fatty-acid oxidation and endurance metabolism. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 453.50 Da | 4,814 Da |
| Half-life | ~20-24 hours | 5 days (120 hours) |
| Bioavailability | Oral | High (SubQ ~80%) |
| Typical dose | Commonly cited 10-20 mg/day (research) | 2.5 mg → titrate up to 15 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Cardarine (GW-501516) reported benefits
- Increased endurance (research claims)
- Enhanced fat oxidation
- No hormonal suppression
- Improved lipid profile in some studies
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.